Article

Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.

Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
The Journal of thoracic and cardiovascular surgery (Impact Factor: 3.41). 06/2007; 133(6):1419-27. DOI: 10.1016/j.jtcvs.2007.01.041
Source: PubMed

ABSTRACT Positron emission tomographic maximal standardized uptake value has been shown to predict survival after resection of non-small cell lung cancer. The relative prognostic benefit of maximal standardized uptake value with respect to other clinical/pathologic variables has not been defined.
We reviewed patients who had positron emission tomographic imaging and an R0 resection for non-small cell lung cancer between January 1, 2000, and December 31, 2004, without induction or adjuvant therapy. The associations between overall survival, histology, pathologic TNM stage, pathologic tumor diameter, and standardized uptake value were tested.
Four hundred eighty-seven patients met the study criteria. Median follow-up was 25.8 months. By using the median values for tumor size (2.5 cm) and standardized uptake value (5.3), standardized uptake value was an independent predictor of survival (P = .03), adjusting for tumor size (P = .02) and histology (P < .01). The optimal standardized uptake value for stratification was identified as 4.4, and this value was identified as an independent predictor of survival (P = .03) after adjusting for clinical TNM stage. Standardized uptake value was not an independent predictor of survival (P = .09), adjusting for pathologic TNM stage (stage IA vs IB vs stage II-IV, P < .01).
Standardized uptake value does not add to the prognostic significance of pathologic TNM stage. Standardized uptake value was an independent prognostic factor from clinical TNM stage.

0 Bookmarks
 · 
50 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic body radiotherapy (SBRT) is commonly considered an important treatment option for patients with stage I non-small cell lung cancer (NSCLC) who have contraindications for surgery or refuse surgery. Many studies have reported that the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) of the primary tumor has prognostic value for resected NSCLC. The purpose of this study was to determine whether SUVmax is a predictor of disease-free survival (DFS) in patients with stage I NSCLC after SBRT. In all patients, the diagnosis was pathologically or cytologically confirmed. The prescription dose was 48 Gy in four fractions at the isocenter. FDG-PET was performed before SBRT. Twenty-nine patients were enrolled in this study. The median follow-up period was 14 months (range, 2-56 months). Regional lymph node metastasis and distant metastasis were observed in 5 (17%) and 2 (7%), respectively. The median SUVmax was 5.6 (range, 2.2-22.0). DFS at 2 years was significantly different between the low SUVmax (<8.0) and high SUVmax (≥8.0) groups (85 versus 17%). In univariate analysis, SUVmax and gross tumor volume were significantly correlated with DFS. Multivariate analysis included variables with P-values <0.20 and showed that only SUVmax was significantly correlated with DFS. Pretreatment SUVmax on FDG-PET predicted the DFS in patients with stage I NSCLC after SBRT.
    Asia-Pacific Journal of Clinical Oncology 10/2013; · 0.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications. Methods A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status. Results EGFR mutations were found in 57 patients (60.8 %). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11.1 ± 5.7 vs. 9.8 ± 4.4, P = 0.103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P = 0.003 and 0.009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P = 0.004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors. Conclusion In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.
    Nuclear Medicine and Molecular Imaging. 09/2012; 46(3).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) using 2-(18F)-flouro-2-deoxy-D-glucose (FDG) has emerged as a useful tool in the clinical work-up of lung cancer. This review article provides an overview of applications of PET in diagnosis, staging, treatment response evaluation, radiotherapy planning, recurrence assessment and prognostication of lung cancer.
    Quantitative imaging in medicine and surgery. 06/2014; 4(3):195-206.